----
Current ValuationThe current P/E ratio is -85.12, within the reasonable range, cheaper than 72.92% of the time in the past 3 years, and the industry ranks 55/58, the industry Median -2.50.
-85.12xP/E
$59.72Stock price
$-0.70Earnings per share
-85.12xP/E
Stock price$59.72Earnings per share$-0.70
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 27.14x
- Typical range
- -235.84x–58.00x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -350.16x | -- | $48.26B |
CRLUSCharles River Laboratorie | -60.12x | 241.81% | $14.34B |
TEMUSTempus AI | -49.61x | 1.28% | $12.62B |
AVTRUSAvantor | -17.96x | 144.24% | $10.38B |
TXGUS10X Genomics | -131.98x | 107.28% | $9.92B |
BRKRUSBruker | -85.12x | 7.71% | $9.10B |
ADPTUSAdaptive Biotechnologies | -65.68x | 39.25% | $4.19B |
ABCLUSAbcellera Biologics | -25.25x | 36.73% | $4.16B |
FTREUSFortrea | -22.95x | 93.77% | $1.96B |
MRVIUSMaravai LifeSciences | -24.93x | 64.44% | $1.93B |
ALMRUSAlamar Biosciences | -38.80x | 80.55% | $1.93B |
PSNLUSPersonalis | -15.94x | 18.68% | $1.71B |
AZTAUSAzenta | -12.79x | 180.77% | $1.57B |
CYRXUSCryoport | -19.36x | 156.25% | $878.76M |
PACBUSPacific Biosc California | -6.43x | 75.69% | $845.46M |
DNAUSGinkgo Bioworks | -2.66x | 35.20% | $772.39M |
CTKBUSCytek Biosciences | -8.61x | 33.98% | $694.11M |
OABIUSOmniAb | -14.98x | 35.96% | $662.98M |
EVOUSEvotec SE | -2.50x | 375.28% | $571.89M |
TKNOUSAlpha Teknova | -27.89x | 5.80% | $467.62M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
